Connor Christou was doing everything right. He tracked his sleep with a Whoop band, cross-referenced it with an Oura ring, and got nearly 100 biomarkers checked annually. He followed longevity research protocols from Peter Attia and Rhonda Patrick. At 35, building his second company, he was about as dialed-in on health optimization as anyone could be.
Then his arm swelled up after a workout.
A week later he saw a doctor, who found two blood clots and scheduled surgery. But pre-op exams changed everything. Doctors found an 11-by-11-by-8 centimeter mass behind his sternum. Biopsy confirmed aggressive non-Hodgkin’s lymphoma — a rare diagnosis affecting roughly one in 420,000 people, caused by a random genetic mutation. No connection to lifestyle, diet, or stress.
The tumor had existed for about three months. Three more weeks and it would have been stage four.
Christou’s first oncologist recommended the lighter of two chemo regimens. He booked the infusion. Then, the night before, he sought a second opinion. That doctor didn’t hesitate — he pushed for the harder, more aggressive treatment. Continuous in-hospital infusion, cycling every three weeks across six months. The lighter option had roughly a 60% success rate for his presentation. The aggressive one brought it to about 85%.
Two world-class doctors. Completely opposite recommendations.
Christou didn’t stop at two opinions. Over the next two days he gathered 12, calling in favors from hematologists and oncologists across the US and abroad. Eleven to one voted for the harder path. He took it.
He approached chemotherapy the way he’d approach building a company — as a marathon of sprints, each with defined cycles and weekly data points. He fed everything into Claude: blood results, scan data, wearable outputs, journal entries. The AI became his research assistant, helping him process information across dozens of treatment decisions.
“As founders, we hold the wheel,” Christou says. “You hear many things. You don’t have to follow the first advice.”
